Amikacin is the aminoglycoside of choice for treatment of severe infections in intensive care. An achievement of its objectives in pharmacokinetics and pharmacodynamics is difficult in intensive care patients because of modification of their volume of distribution and renal clearance. Acute renal failure requiring renal replacement therapy is frequent in intensive care. Extrarenal purification modalities (continuous versus intermittent, type of dialysis membrane), which can influence amikacin clearance, are multiple and teams dependent. Guidelines of good practice for Amikacin in intensive care patients do not exist.

The aim of this study is to describe strategies of prescription and monitoring of Amikacin in intensive care patients on renal replacement therapy.

inclusion criteria :

• patients in intensive care
• patients on extrarenal replacement
• patients with Amikacin treatment
• patients accepting to participate in the study

exclusion criteria :

• patients less than 18 years old
• pregnant women
• patients with Amikacin treatment in the previous 7 days

Intensive care patients on renal replacement therapy with Amikacin treatment